Sclerosis multiplex (SM): vizsgálatok itt: Ausztrália
14 trials · From ClinicalTrials.gov, checked 2026. november 11.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
- Where
- Melbourne
- Életkor
- 18 év to 60 év
- People
- 705 worldwide
- Run by
- Zenas BioPharma (USA), LLC
See details and how to joinNCT07067463 · EU 2025-524316-11-00 - 3. fázisTaking peopleA Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
- Where
- Kogarah
- Életkor
- 18 év to 60 év
- People
- 990 worldwide
- Run by
- Zenas BioPharma (USA), LLC
See details and how to joinNCT07299019 · EU 2025-524322-18-00 - 2. fázisTaking peopleA Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity
- Where
- Box Hill, Heidelberg, Hobart, Kent Town, Nedlands, Newcastle, Parkville, Sydney
- Életkor
- 18 év to 70 év
- People
- 200 worldwide
- Run by
- Celgene
See details and how to joinNCT06782490 - 3. fázisTaking peopleEfficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
- Where
- Liverpool, Melbourne, Parkville, St Leonards
- Életkor
- 40 év to 70 év
- People
- 400 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT06846281 · EU 2023-509275-17-00 - 1. fázisTaking peopleStudy of KITE-363 in Participants With Autoimmune Neurologic Diseases That Did Not Respond to Usual Treatment
- Where
- Sydney, Westmead
- Életkor
- 18 év to 75 év
- People
- 57 worldwide
- Run by
- Kite, A Gilead Company
See details and how to joinNCT07304154 - No phaseNot yet taking people in AusztráliaAn Online Tailored Cognitive Therapy-Based Intervention for Depression in Multiple Sclerosis: ACTION-MS Online
- Where
- Melbourne
- Életkor
- 18 év and over
- People
- 240 worldwide
- Run by
- University of Melbourne
See details and how to joinNCT07875309 - 3. fázisTaking peopleA Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
- Where
- Clayton, Heidelberg, Kogarah, Murdoch, New Lambton Heights, Southport, Westmead
- Életkor
- 18 év to 65 év
- People
- 1275 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07225504 - 2. fázisTaking peopleA Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)
- Where
- Box Hill, Camperdown, Heidelberg, Kogarah, New Lambton Heights
- Életkor
- 18 év to 60 év
- People
- 360 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07282574 · EU 2025-521636-10-00 - 1/2. fázisTaking peopleA Phase 1/2a Study of Oral PRO-1562 in Healthy Subjects and Patients With Relapsing Multiple Sclerosis
- Where
- Adelaide
- Életkor
- 18 év to 65 év
- People
- 160
- Run by
- Progentos Therapeutics
See details and how to joinNCT07826689 - 3. fázisTaking peopleStudy to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis
- Where
- Melbourne
- Életkor
- 10 év to 17 év
- People
- 194 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT06408259 · EU 2022-501332-42-00 - 1. fázisTaking peopleAn Open-label Study of AZD0120 in Adults With Multiple Sclerosis
- Where
- Liverpool, Melbourne, Waratah
- Életkor
- 18 év to 60 év
- People
- 24 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07224373 - No phaseTaking peoplePregnancy Exposure Registry for Vumerity (Diroximel Fumarate)
- Where
- Heidelberg
- People
- 908 worldwide
- Run by
- Biogen
See details and how to joinNCT05658497 - 1/2. fázisTaking peopleSafety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VT7208 in Healthy Participants and MS Patients
- Where
- Adelaide
- Életkor
- 18 év to 65 év
- People
- 100
- Run by
- Vidya Therapeutics Inc
See details and how to joinNCT07085507 - 2. fázisTaking peopleA Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years
- Where
- Birtinya
- Életkor
- 18 év to 55 év
- People
- 180 worldwide
- Run by
- ModernaTX, Inc.
See details and how to joinNCT06735248 · EU 2024-517949-13-00